CD4 and cancer: However, peptide-based anti-cancer vaccines encountered several limitations in the clinical setting due to several reasons including the following: (1) there is lack of CD4+ T cell help, (2) peptides are prone to degradation, (3) they may induce tolerance, (4) they induce low magnitude or transient immune response, and (5) there is dysfunction of DCs upon cancer [4, 22].